AbbVie, ụlọ ọrụ biopharmaceutical zuru ụwa ọnụ nke dabere na nyocha, mara ọkwa Health Canada akwadoro SKYRIZI® (risankizumab), maka ọgwụgwọ nke ndị ọrịa toro eto nwere ọrịa ogbu na nkwonkwo psoriatic. Na PsA, enwere ike iji SKYRIZI naanị ya ma ọ bụ yana yana ọgwụ antirheumatic na-agbanwe ọrịa na-abụghị nke ndu (cDMARD) (dịka ọmụmaatụ, methotrexate).
“SKYRIZI ịnata ọkwa nke nnabata maka ọgwụgwọ ọrịa ogbu na nkwonkwo na-arụsi ọrụ ike na-enye ndị ọrịa olileanya ọzọ. Nsonaazụ sitere na mmemme nnwale ụlọ ọgwụ nke Phase 3 na-egosi mmụba na akara na mgbaàmà metụtara ọrịa a,” Dr. Kim Alexander Papp, MD, PhD, FRCPC, FAAD, Nnyocha Ahụike Probity kwuru.
"Na AbbVie, anyị na-agbalịsi ike ịgbanwe ụkpụrụ nlekọta maka ndị na-adịghị ahụkebe, anyị na-enwekwa obi ụtọ na nkwado Health Canada nke SKYRIZI maka ọgwụgwọ ndị okenye nwere ọrịa ogbu na nkwonkwo na-arụ ọrụ," Tracey Ramsay, onye isi oche na onye isi nchịkwa, AbbVie Canada kwuru.
Nke a bụ ihe ngosi nke abụọ maka SKYRIZI na Canada. N'April 2019, Health Canada kwadoro SKYRIZI maka ọgwụgwọ nke ndị ọrịa toro eto nwere psoriasis dị oke oke ma dị njọ bụ ndị na-aga maka usoro ọgwụgwọ ma ọ bụ phototherapy.
IHE Ị GA-Ewepụ na edemede a:
- "Na AbbVie, anyị na-agba mbọ ịgbanwe ụkpụrụ nlekọta maka ndị na-adịghị ahụkebe, anyị na-enwekwa obi ụtọ na nkwado Health Canada nke SKYRIZI maka ọgwụgwọ ndị okenye nwere ọrịa ogbu na nkwonkwo na-arụ ọrụ,".
- N'April 2019, Health Canada kwadoro SKYRIZI maka ọgwụgwọ nke ndị ọrịa toro eto nwere psoriasis dị oke oke ma dị njọ bụ ndị na-aga maka usoro ọgwụgwọ ma ọ bụ phototherapy.
- In PsA, SKYRIZI can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.
